The TRAMPOLINE VT Study
Key facts
- Who runs it
- Barts & The London NHS Trust
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 10 people enrolled
- Started
- 21 Nov 2022
- Ended
- 23 Sept 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Octaray catheter
- Standard of care
- Record updated
- 25 March 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- ICD in situ
- Clinical indication for VT ablation; incessant VT or receiving appropriate ICD therapies for VT despite anti-arrhythmic drugs
- Ischaemic or non-ischaemic heart disease
Who cannot take part
- Cardiotomy within previous 3 months
- Valvular heart disease precluding LV access
- Acute coronary syndrome within 6 weeks
- Dialysis patients
- Coagulopathy/Thrombocytopaenia
- Pregnancy/breastfeeding women
- CMR contraindicated
- Prognosis <12 months
- Unable to provide informed consent
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This non-randomised, prospective trial will examine the feasibility and efficacy of VT ablation guided by activation mapping using the Octaray and Optrell catheters. Annotation algorithms within the CARTO3 electro-anatomical mapping system will be integrated with 3D scar segmentation data from cardiac MRI (ADAS-VT), and extrastimulus voltage mapping will identify sites of interest for focussed activation mapping. The investigators hypothesise that the examination of these data will identify critical target sites for ablation. Intra-procedural diagnostic performance of the Octaray and Optrell catheters will be assessed as the primary outcome, and will be compared with the standard of care. Secondary, clinical outcomes - primarily the need for ICD therapies at 12 months post ablation - will be compared with propensity-matched controls undergoing substrate-based ablation alone. Follow-up MRI scans will review the impact of ablation on the elimination of conduction channels.
The 2 groups in the trial
- Octaray catheterTreatment being tested
VT ablation guided by activation mapping using the Octaray catheter and integrated cardiac MRI data.
- Standard of careExisting treatment, for comparison
Identified retrospectively from registry data: propensity matched-controls undergoing VT ablation guided by substrate-modification alone.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Trial of Rapid Activation MaPping Using a nOveL Catheter and Integrated Non-invasivE Imaging in Ventricular Tachycardia
- Publications
- Record updated
- 25 March 2025